{"name":"Oasmia Pharmaceutical AB","slug":"oasmia-pharmaceutical-ab","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Paclical®","genericName":"Paclical®","slug":"paclical","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"Paclical®","genericName":"Paclical®","slug":"paclical","phase":"phase_3","mechanism":"Paclical is a formulation of paclitaxel, a microtubule inhibitor that disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells.","indications":["Non-small cell lung cancer","Ovarian cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPanNWdUZyeUtQY2MwOGRPQTlDUzZUNzQwYVJ1LWJ5N2puZExHNWRZVDFPRzNyWEtZU0tyVGk0c2RUNzhRbW9FM1Nicmxqci13cnR3R2tHWkp3a3YyZHVvSXQ5YmttYl9Ha2RrVkQxWmViX1hiQm5XbkR5a3YtMzE4MHBoRzlTNU1mTVlGVGhDeHpoY2JYZ0FB?oc=5","date":"2026-04-07","type":"trial","source":"openPR.com","summary":"In-Depth Study of Segments, Industry Developments, and Key Players in the Pet Cancer Therapeutics Market - openPR.com","headline":"In-Depth Study of Segments, Industry Developments, and Key Players in the Pet Cancer Therapeutics Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOX2R2U1JVaVRyQk1KRXN0a2o0Q2xiUnBXSklDNkZnVDNFVl9QQjUySm9uV2dVeUZSa3dRcmc2YnRWVGVlVEZ2UElMbTZsZGsybzMwZnhCejB0MmRLbDZVTjNSX09rR0IyOUw3OExWckR4T20zcGFRZ0hsU1o3UmhTN182MlBxZ0F3THBkV3RJdkhVMHA1b2QxNVFBQnNaQjVyR01HZXRSdTVrNUJ4aTMtemRPQTItTHdERVU3b2VvVmlybnAx?oc=5","date":"2025-12-29","type":"pipeline","source":"TradingView","summary":"Boule Diagnostics appoints Michael af Winklerfelt as new CFO - TradingView","headline":"Boule Diagnostics appoints Michael af Winklerfelt as new CFO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPS1MtdFIwZmlPN0FqeGo1b2wwa0RFc2pHaktUN3pmOEN2di13QjNoMmc1VmpEeE83TUdtSFRCNFhZdFZnQVhwVlkwN05pNy1HYlU1ZnNiVTQ5d2FrOVlvUkl5UFdQUGRLc3M1bU12WjhOa1NRb2RCdUN5X1VWU2tLMVc3NWJlSXozc3ZBZTZzV25FUkJMZG5NUDUyb1hBN29hX2dHTzd2dw?oc=5","date":"2017-11-08","type":"pipeline","source":"twst.com","summary":"Julian Aleksov and Anders Blom Chart Bold New Course for Biotech Firm Oasmia (NASD:OASM) - twst.com","headline":"Julian Aleksov and Anders Blom Chart Bold New Course for Biotech Firm Oasmia (NASD:OASM)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQX2E2MlRMdTd5NGxSVzNIdEE0OGJJak9reVpoNFBLMGdSbEVYQ2JhTHFseDREeno1UEJCdHpRcENpVHIyajF6cHJKd2o3YUN3WmdWMzRDeVA4NDhsa2tzY3BMb0FOTy02Z0xYWGxDcjdUUE9hR2t2WDBrY3o3VVQwTC1ZZ3oyQXVTYk1OUTRRNXI0Umx0cTI3RGRGLUpiVjQtbjlpd3ZXV3BPZw?oc=5","date":"2016-09-02","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders: Novo Nordisk says goodbye to CEO Lars Rebien Sorensen - Fierce Biotech","headline":"Chutes & Ladders: Novo Nordisk says goodbye to CEO Lars Rebien Sorensen","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}